| Formulation | 50KPO4,7.5mMKCl,75uMEDTApH7.4 |
| MolecularWeight | |
| Storage | -80°C |
| Purity | >95%bySDS-PAGE |
| Compound | |
| Assay | Plasmininhibitionassay |
| ShelfLife(properlystored) | 12months |
| ChemicalFormula | |
a2–plasmininhibitorandfibrinolysis
Theprimaryphysiologicalinhibitorofplasminisa2–plasmininhibitor.Thebindingofa2–plasmininhibitortoplasmin(ogen)playsacriticalroleinfibrinolysis.Thebindingofcirculatingfreeplasmin(ogen)bya2–plasmininhibitorpreventsbothzymogenandenzymefrombindingtofibrinandultimatelyinitiatingfibrinolysis.a2–Plasmininhibitoralreadycrosslinkedtofibrinpreventsplasmincatalyticactiononlocalsitesoffibrindepositionaswellasimpedingsubsequentactivationofplasminogenviaplasminogenactivator.
SampleGelInformation:
| Gel | Novex4-12%Bis-Tris |
|---|---|
| Load | Humanα2–PlasminInhibitor,1µgperlane |
| Buffer | MOPS |
| Standard | SeeBluePlus2;Myosin(191kDa),PhosphorylaseB(97kDa),BSA(64kDa),GlutamicDehydrogenase(51kDa),AlcoholDehydrogenase(39kDa),CarbonicAnhydrase(28kDa),MyoglobinRed(19kDa),Lysozyme(14kDa) |
Overview:
α2–plasmininhibitor(α2-PI)isasingle-chainglycoproteinandisoneofthemajorserineproteinaseinhibitorscirculatinginplasma.Physiologically,itisthepredominantinhibitorofplasminanditthereforeplaysasignificantroleinthespecificinhibitionoffibrinolysis.Theroleofα2-PIinfibrinolysisisthreefold:covalentinhibitionofplasmin;interferencewiththebindingofplasminogentofibrin;andfactorXIIIacatalyzedcross-linkingofα2-PItofibrin(1).Rapidinactivationofplasminproteolyticactivityoccursthroughatwo-stepprocess.TheinhibitorfirstformsareversIBLecomplexwithplasminwhichissub-sequentlyfollowedbytheformationofacovalent,enzymaticallyinactive,complexwiththecatalyticsiteinplasmin(2,3).α2-PIalsofunctionsbyinterferingwiththebindingofplasminogentofibrin,effectivelyslowingtheactivationofplasminogenbyfibrin-boundplasminogenactivator(4).Theinterferenceinbindingultimatelydelaystheinitiationoffibrinolysis.Covalentcross-linkingofa2-PItothea-chainsoffibrinwhichismediatedbyfactorXIIIa,protectscrosslinkedfibrinclotsfromplasmindegradationandtherebymarkedlystABIlizesthefibrinclotagainstfibrinolysis(5).Failuretoprotectthefibrinclotfromrapiddissolutionbeforeinjuredvesselscanberestoredresultsinableedingtendencydescribedinpatientswithadeficiencyinα2-PIorfactorXIII(6,7).
Properties:
| Localization | Plasma |
|---|---|
| Modeofaction | Inhibitsplasminbyforminganirreversiblecomplexwiththecatalyticactivesite.Preventsthebindingofplasmintofibrin.Cross-linkedbyfactorXIIIatofibrin. |
| PlasmaConcentration | 69µg/ml(1) |
| Molecularweight | 58,700single-chain(determinedfromaminoacidsequenceand14%carbohydrate)and67,000(determinedbySDS-PAGE)(1) |
| Extinctioncoefficient | E1%1cm,280nm=14.5(human)(9) |
| IsoelectricPoint | Unknown |
| Structure | Circulatesassinglechainmoleculeconsistingof452aminoacids(1). |
| Percentcarbohydrate | 14%(w/w)(1) |
